TIMP1 and breast carcinoma: A change in TIMP1 expression could mediate resistance to gemcitabine in pancreatic cancer [56,57], to fulvestrant in MCF-7 human breast cancer cells [58], to platinum in epithelial ovarian cancer [59], to carboplatin in lung cancer [60], and to antiestrogen in breast cancer [61].